Conference Reports for NATAP

Back

HIV DART 2008 December 9-12, 2008 Rio Grande, Puerto Rico     Hydroxyurea+ddI Returns, Franco Lori Presents: A "Virostatic" Approach to Antiretroviral Therapy: Beyond ddI/Hydroxyurea? - Written for NATAP by Mark Mascolini - (12/12/08)   This is Your Brain Off Drugs: Neurocognitive Function before and after Antiretroviral Treatment Discontinuation in Patients with High CD4 Nadir (ACTG A5170). - (12/12/08)   Women's HIV Care and Treatment Access for African-Americans and the GRACE Study - (12/12/08)   Raltegravir Efficacy and Safety After 96 Weeks of Phase 2 Trial - Written for NATAP by Mark Mascolini - (12/12/08)   Darunavir vs Lopinavir at 96 Weeks in People With Naïve Advanced HIV - ARTEMIS Study - Written for NATAP by Mark Mascolini - (12/12/08)   Dropout Rate in Study of US Minority Women Near 25% at 24 Weeks Written for NATAP by Mark Mascolini - (12/11/08)   Siliciano Proposes Novel Gauge of Antiretroviral Activity Written for NATAP by Mark Mascolini - (12/11/08)   Foot-Fractures in HIV+ Men Written for NATAP by Mark Mascolini - (12/11/08)   Early Results With Antiretrovirals Plus Immunotoxins That Target Viral Reservoirs Written for NATAP by Mark Mascolini - (12/11/08)